See original story here Encyt Technologies, Inc., a leading biotech cancer research organization based in Nova Scotia, Canada, recently filed a series of patents for novel treatments to reverse resistance to immunotherapy using checkpoint inhibitors. According to Dr. William Harless, MD/PhD, and Encyt CEO: “ENCYT has been studying the expression pattern of a number of distinct cytokines…

2015 © Copyright - Bionova